Hikal Limited (HIKAL.BO)
INR 419.05
(9.18%)
INR 419.05
(9.18%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 7.96 Billion INR | 10.43% |
| 2022 | 7.21 Billion INR | 8.72% |
| 2021 | 6.63 Billion INR | 10.12% |
| 2020 | 6.02 Billion INR | -1.88% |
| 2019 | 6.14 Billion INR | -5.44% |
| 2018 | 6.49 Billion INR | 3.21% |
| 2017 | 6.29 Billion INR | 5.6% |
| 2016 | 5.95 Billion INR | -0.02% |
| 2015 | 5.96 Billion INR | 9.89% |
| 2014 | 5.42 Billion INR | 22.52% |
| 2013 | 4.42 Billion INR | -22.49% |
| 2012 | 5.71 Billion INR | 28.55% |
| 2011 | 4.44 Billion INR | -15.6% |
| 2010 | 5.26 Billion INR | 8.43% |
| 2009 | 4.85 Billion INR | -13.49% |
| 2008 | 5.61 Billion INR | 31.48% |
| 2007 | 4.26 Billion INR | 66.05% |
| 2006 | 2.57 Billion INR | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | 208.8 Million INR | -97.38% |
| 2023 FY | 7.96 Billion INR | 10.43% |
| 2023 Q1 | 595.5 Million INR | -91.75% |
| 2023 Q2 | 7.62 Billion INR | 1180.45% |
| 2023 Q3 | 361 Million INR | -95.27% |
| 2023 Q4 | 7.96 Billion INR | 2106.93% |
| 2022 Q3 | 506.7 Million INR | -92.36% |
| 2022 Q1 | 593.6 Million INR | -91.05% |
| 2022 Q4 | 7.21 Billion INR | 1323.83% |
| 2022 FY | 7.21 Billion INR | 8.72% |
| 2022 Q2 | 6.63 Billion INR | 1017.89% |
| 2021 Q1 | 368.1 Million INR | -93.89% |
| 2021 FY | 6.63 Billion INR | 10.12% |
| 2021 Q2 | 6.13 Billion INR | 1566.45% |
| 2021 Q4 | 6.63 Billion INR | 962.57% |
| 2021 Q3 | 624.5 Million INR | -89.82% |
| 2020 Q2 | 5.39 Billion INR | 747.92% |
| 2020 Q3 | 371.8 Million INR | -93.1% |
| 2020 Q4 | 6.02 Billion INR | 1520.8% |
| 2020 FY | 6.02 Billion INR | -1.88% |
| 2020 Q1 | 635.7 Million INR | -89.65% |
| 2019 FY | 6.14 Billion INR | -5.44% |
| 2019 Q4 | 6.14 Billion INR | 1588.69% |
| 2019 Q3 | 363.7 Million INR | -93.96% |
| 2019 Q2 | 6.02 Billion INR | 1811.51% |
| 2019 Q1 | 315.17 Million INR | -95.15% |
| 2018 FY | 6.49 Billion INR | 3.21% |
| 2018 Q4 | 6.49 Billion INR | 0.0% |
| 2018 Q1 | 269.87 Million INR | 0.0% |
| 2017 FY | 6.29 Billion INR | 5.6% |
| 2016 FY | 5.95 Billion INR | -0.02% |
| 2015 FY | 5.96 Billion INR | 9.89% |
| 2014 FY | 5.42 Billion INR | 22.52% |
| 2013 Q4 | 4.42 Billion INR | 0.0% |
| 2013 FY | 4.42 Billion INR | -22.49% |
| 2012 Q2 | 4.49 Billion INR | 0.0% |
| 2012 Q4 | 5.71 Billion INR | 0.0% |
| 2012 FY | 5.71 Billion INR | 28.55% |
| 2011 FY | 4.44 Billion INR | -15.6% |
| 2010 FY | 5.26 Billion INR | 8.43% |
| 2009 FY | 4.85 Billion INR | -13.49% |
| 2008 FY | 5.61 Billion INR | 31.48% |
| 2007 FY | 4.26 Billion INR | 66.05% |
| 2006 FY | 2.57 Billion INR | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Sun Pharmaceutical Industries Limited | -72.47 Billion INR | 110.993% |
| NATCO Pharma Limited | -5.81 Billion INR | 236.961% |
| Suven Pharmaceuticals Limited | 144.97 Million INR | -5395.392% |
| Syncom Formulations (India) Limited | 46.21 Million INR | -17140.484% |
| Achyut Healthcare Limited | -3.74 Million INR | 212780.192% |
| Ajanta Pharma Limited | -954.9 Million INR | 934.328% |
| Alkem Laboratories Limited | -1.6 Billion INR | 595.029% |
| Alpa Laboratories Limited | 35.36 Million INR | -22429.197% |
| Alembic Pharmaceuticals Limited | 3.86 Billion INR | -106.084% |
| AstraZeneca Pharma India Limited | -5.01 Billion INR | 258.945% |
| Aurobindo Pharma Limited | 3.69 Billion INR | -115.715% |
| Bajaj HealthCare Limited | 3.29 Billion INR | -141.501% |
| Bliss GVS Pharma Limited | -1.15 Billion INR | 788.144% |
| Brooks Laboratories Limited | 49.48 Million INR | -15999.828% |
| Divi's Laboratories Limited | -39.77 Billion INR | 120.033% |
| Dr. Reddy's Laboratories Limited | 12.91 Billion INR | 38.302% |
| Eris Lifesciences Limited | 13.8 Billion INR | 42.295% |
| FDC Limited | -57.75 Million INR | 13895.193% |
| Glenmark Pharmaceuticals Limited | -4.28 Billion INR | 285.916% |
| Glenmark Life Sciences Limited | -2.84 Billion INR | 380.266% |
| Granules India Limited | 9.28 Billion INR | 14.211% |
| Gufic Biosciences Limited | 3.19 Billion INR | -149.412% |
| Hester Biosciences Limited | 2.29 Billion INR | -247.792% |
| Indoco Remedies Limited | 6.47 Billion INR | -23.018% |
| Ind-Swift Laboratories Limited | -4.15 Billion INR | 291.835% |
| Ipca Laboratories Limited | 11.41 Billion INR | 30.207% |
| Jagsonpal Pharmaceuticals Limited | -1.38 Billion INR | 673.194% |
| Krebs Biochemicals & Industries Limited | 1.93 Billion INR | -312.174% |
| Lasa Supergenerics Limited | 205.79 Million INR | -3771.253% |
| Laurus Labs Limited | 24.38 Billion INR | 67.328% |
| Lupin Limited | 17.19 Billion INR | 53.659% |
| Mankind Pharma Limited | -9.9 Billion INR | 180.41% |
| Medicamen Biotech Limited | 160.31 Million INR | -4869.56% |
| Medico Remedies Limited | 78.67 Million INR | -10026.212% |
| Megasoft Limited | 1.28 Billion INR | -519.734% |
| Piramal Pharma Limited | 42.27 Billion INR | 81.155% |
| RPG Life Sciences Limited | -364.7 Million INR | 2284.535% |
| Sigachi Industries Limited | 859.94 Million INR | -826.45% |
| Sun Pharma Advanced Research Company Limited | -941.8 Million INR | 945.933% |
| Unichem Laboratories Limited | 931.91 Million INR | -754.905% |
| Wanbury Limited | 1.1 Billion INR | -620.425% |
| Windlas Biotech Limited | -273.04 Million INR | 3017.887% |
| ZIM Laboratories Limited | 983.6 Million INR | -709.98% |
| Zydus Lifesciences Limited | 3.91 Billion INR | -103.655% |
| Procter & Gamble Health Limited | -2.34 Billion INR | 439.31% |
| Amrutanjan Health Care Limited | -248.79 Million INR | 3302.273% |
| Bal Pharma Limited | 1.26 Billion INR | -530.52% |
| Strides Pharma Science Limited | 23.25 Billion INR | 65.744% |
| Venus Remedies Limited | -267.7 Million INR | 3076.093% |
| Aarti Pharmalabs Limited | 2.61 Billion INR | -205.027% |
| Nectar Lifesciences Limited | 6.15 Billion INR | -29.391% |
| Shilpa Medicare Limited | 9.06 Billion INR | 12.156% |
| Aarti Drugs Limited | 5.54 Billion INR | -43.591% |
| IOL Chemicals and Pharmaceuticals Limited | -1.1 Billion INR | 823.418% |
| Suven Life Sciences Limited | -1.63 Billion INR | 587.965% |
| Ind-Swift Limited | 9.5 Billion INR | 16.213% |
| Valiant Laboratories Limited | -295.03 Million INR | 2800.385% |
| J. B. Chemicals & Pharmaceuticals Limited | 2.82 Billion INR | -182.398% |
| Solara Active Pharma Sciences Limited | 10.02 Billion INR | 20.56% |
| Themis Medicare Limited | 764.96 Million INR | -941.49% |
| Torrent Pharmaceuticals Limited | 31.83 Billion INR | 74.97% |
| Sequent Scientific Limited | 4.17 Billion INR | -90.661% |
| Novartis India Limited | -5.89 Billion INR | 235.238% |
| Wockhardt Limited | 18.27 Billion INR | 56.393% |
| Jubilant Pharmova Limited | 27.07 Billion INR | 70.571% |
| Biofil Chemicals and Pharmaceuticals Limited | -18.44 Million INR | 43290.936% |
| Neuland Laboratories Limited | -214.05 Million INR | 3821.888% |
| Morepen Laboratories Limited | -231.17 Million INR | 3546.322% |
| Kilitch Drugs (India) Limited | 120.03 Million INR | -6537.01% |
| Mangalam Drugs & Organics Limited | 975.81 Million INR | -716.449% |